Navigation Links
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
Date:2/13/2009

ivalents and marketable securities totaled $12.9 million compared to $16.8 million at June 30, 2008. As previously announced, the Company borrowed $5.0 million from Robert W. Duggan & Associates on December 30, 2008, with interest payable in arrears at 1.36% until March 31, 2009; at Citibank prime rate from April 1, 2009 until December 31, 2009; and at the prime rate plus 2% from January 1, 2010 until July 1, 2010. The principal amount of the loan has been discounted to fair value for balance sheet presentation as a result of the below market interest rates. The accretion of the discount will cause an increase in the carrying amount of indebtedness, and in charges to interest expense, from December 31, 2008 to June 30, 2009 of $500,000.

Fiscal 2009 Guidance

Pharmacyclics projects total operating expenses, excluding share-based compensation, of between $9 and $10 million for the remaining two quarters of fiscal year 2009, including general and administrative expenses of approximately $3 million. Including share-based compensation expense, Pharmacyclics projects total operating expenses of between $10 and $11 million for the remaining two quarters of fiscal year 2009, including general and administrative expenses of approximately $3.5 million. Financial projections involve a high level of uncertainty due to, among other factors, the variability involved in predicting requirements of early stage research programs and clinical trials, the potential for entering into partnering arrangements or strategic collaborations, the timing of U.S. Food and Drug Administration (FDA) decisions and share-based compensation expense.

Robert W. Duggan stated, "Through the December quarter and up to the date of this press release we have made solid progress on numerous fronts. Financially we closed a $5,000,000 million loan on favorable terms. We have also concluded our review of MGd for the potential treatment
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
2. Pharmacyclics Secures $5.0 Million in Debt Financing
3. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
4. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
5. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
6. Pharmacyclics Announces It Received Nasdaq Notification
7. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
8. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
9. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
10. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
11. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... development of botanical and plant-derived compounds. BCC Research reveals in its new ... 2020 because this market defines the category and generates the most market demand. ...
(Date:9/2/2015)... Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... , president and chief executive officer, will present at ... 16, 2015 at 10:30 a.m. ET in ... live audio webcast and subsequent replay may be accessed ... be available shortly after conclusion of the presentation and ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... critical demand to aid high-risk surgeries. From vital sign monitoring in ICU to ... Intel technology enables surgeon to make real-time clinical decisions with simultaneous access to ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
... Middleton-based Bone Care International Inc. announced on Wednesday that ... , ,Genzyme and Bone Care have signed a definitive agreement ... all-cash transaction valued at $33.00 per fully diluted ... Bone Care's shareholders at a meeting on June 30, and ...
... Perhaps its time to declare 2005 as the Year ... would say its past time. , ,At last ... headline speakers were successful women with words of advice ... included Kay Koplovitz, a South Milwaukee native who launched ...
... today announced that three Wisconsin businesses will receive funding ... Technology Matching Grant (TMG) and Technology Venture Fund (TVF) ... Technologies, Inc., and Bell Brook Labs, LLC, Meanwhile ... merger. , ,Original air date: Saturday, June 18, 2005 ...
Cached Biology Technology:Women entrepreneurs are finding ways to succeed in Wisconsin and beyond 2Women entrepreneurs are finding ways to succeed in Wisconsin and beyond 3
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions , ... entire spectrum of clinical research, is proud to announce ... company,s comprehensive SaaS-based eClinical technology platform, has led the ... first two quarters of 2015.   Q2 2015 and ... quarters measured by contract value sold in the company,s ...
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/10/2015)... The latest 364 page report from business intelligence provider ... border security market . Visiongain assesses that this ... Now: Border security is hard to achieve and harder to ... you need to know about - and more importantly, you ... this will impact your company and the border security industry ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... Center faculty have been elected to the Institute of Medicine ... Election to the Institute of Medicine (IOM) is one of ... and Columbia now has 49 members in this esteemed organization. ... Carolyn Westhoff were among the 65 new IOM members ...
... of the three most frequent malignancies in Western ... patients with early stage and local CRC approaches ... recurrence and the development of distant metastases that ... cause of CRC-related mortality. Although IL-8 ...
... publishers, has entered a publishing partnership with the Estuarine ... Appearing six times a year, the journal plays ... of estuarine and coastal ecosystems. The first issue ... partnership will be officially announced at the ERF 2007 ...
Cached Biology News:3 Columbia University Medical Center faculty elected to Institute of Medicine 2Interleukin-8, key marker for colorectal cancer treatment 2Estuarine Research Federation chooses Springer as publishing partner 2
Glutamate Receptor 5/1a...
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
... monoclonal [EP282Y] to Asparagine synthetase ... tested applications). ... to residues in the C-terminus ... Entrez GeneID: ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: